Eicosanoid precursor polyenoic fatty acids modulate synaptic levels of dopamine in Ex-Vivo slices of rat brain striatum

In Vivo

Volumn 17, Issue 1, 2003, Pages 83-88

  Davidson, Bruce C ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Brain; Dopamine; Polyenoic fatty acid; Rat; Striatum

Indexed keywords

ARACHIDONIC ACID; BUFFER; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; DOPAMINE; FATTY ACID; FATTY ACID DERIVATIVE; ICOSANOID; ICOSAPENTAENOIC ACID; INDOMETACIN; LINOLEIC ACID; NORDIHYDROGUAIARETIC ACID; OLEIC ACID; POLYENE FATTY ACID; PROSTAGLANDIN SYNTHASE; STEARIC ACID; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EXPOSURE; ELECTROSTIMULATION; EX VIVO STUDY; FATTY ACID METABOLISM; IN VITRO STUDY; ISOTOPE LABELING; MALE; METABOLIC REGULATION; NONHUMAN; RAT; SYNAPTIC TRANSMISSION; TISSUE PERFUSION; TYPES OF STUDY;

EID: 0037237548     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Davidson BC, Kurstjens NP, Patton J and Cantrill RC: Essential fatty acids modulate apomorphine activity at dopamine receptors in cat caudate slices. Eur J Pharmacol 149: 317-322, 1988.
2. Knazek RA and Liu SC: Dietary essential fatty acids are required for maintenance and duction of prolactin receptors. Proc Soc Exp Biol Med 162: 346-350, 1979.
3. Poddubiuk Zm and Kleinrok Z: A comparison of the central actions of prostaglandins A1, E1, E2, F1-alpha and F2-alpha in the rat. II. The effect of intraventricular prostaglandins on the action of some drugs and on the level and turnover of biogenic amines in the rat brain. Psychopharmacology 50: 95-102, 1976.
4. Shimizu T and Wolfe LS: Arachidonic acid cascade and signal transduction. J Neurochem 55: 1-15, 1990.
5. Chalon S, Vancassel S, Zimmer L, Guilloteau D and Durand G: Polyunsaturated fatty acids and cerebral function-focus on monoaminergic neurotransmission. Lipids 36: 937-944, 2001.
6. Fernstrom JD: Effects of dietary polyunsaturated fatty acids on neuronal function. Lipids 34: 161-169, 1999.
7. Vaddadi KS and Gilleard CJ: Essential fatty acids, tardive dyskinesia and schizophrenia. In: Omega Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine (Horrobin DF ed). New York, Alan R Liss, 1990, pp 333-343.
8. Vaddadi KS: Essential fatty acids and neuroleptic drug tardive dykinesia - Preliminary clinical observations. IRCS Med Sci 12: 678, 1984.
9. Vaddadi KS, Courtney P, Gilleard CJ, Manku MS and Horrobin DF: A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 27: 313-323, 1989.
10. Adams PB, Lawson S, Sanigorski A and Sinclair AJ: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 Supplement: 157-161, 1996.
11. Glen E, MacDonell L, Glenn I and MacKenzie J: Possible pharmacological approaches to the prevention and treatment of alcohol-related CNS impairment: Results of a double-blind trial of essential fatty acids. In: Pharmacological Treatments for Alcoholism (Edwards G and Littleton J, eds). London, Croom Helm, 1984, pp 331-350.
12. Horrobin DF: The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukotrienes EFAs 31: 181-197, 1988.
13. Costal B, Kelly EM and Naylor RJ: The antidyskinetic action of dihomo-gamma-linolemic acid in the rodent. Br J Pharmacol 83: 733-740, 1984.
14. Nakada T, Kwee IL and Ellis WG: Membrane fatty acid composition shows delta-6-desaturase abnormalities in Alzheimer's disease. Neuroreport 1: 153-155, 1990.
15. Kodas E, Page G, Zimmer L, Vancassel S, Guilloteau D, Durand G and Chalon S: Neither the density nor function of striatal dopamine transporters were influenced by chronic n-3 polyunsaturated fatty acid deficiency in rodents. Neurosci Lett 32: 95-99, 2002.
16. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Lequisquet AM, Besnard JC and Durand G: Dietary fish oil affects monoaminergic neurotransmission and behaviour in rats. J Nutr 128; 2512-2519, 1998.
17. Kodas E, Vancassel S, Lejeune B, Guilloteau D and Chalon S: Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: Critical role of developmental stage. J Lipid Res 43: 1209-1219, 2002.
18. Carrie I, Clement M, De Javel D, Frances H and Bourre JM: Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. J Lipid Res 41: 465-472, 2000.
19. Favreliere S, Barrier L, Durand G, Chalon S and Tallineau C: Chronic dietary n-3 polyunsaturated fatty acids deficiency affects the fatty acid composition of plasmenylethanolamine and pho sphatidylethanolamine differently in rat frontal cortex, striatum, and cerebellum. Lipids 33: 401-407, 1998.
20. Welsinger HS, Vingrys AJ and Sinclair AJ: Dietary manipulation of long-chain polyunsaturated fatty acids in the retina and brain of guinea pigs. Lipids 30: 471-473, 1995.
21. Bourre JM, Bonneil M, Dumont O, Piciotti M, Nalbone G and Lafont H: High dietary fish oil alters the brain polyunsaturated fatty acid composition. Biochim Blophys Acta 960: 458-461, 1988.
22. Brenner RR: The role of polyunsaturated fatty acids. In: The Role of Fats in Human Nutrition (Vergroesen AJ and Crawford M, eds) San Diego, Academic Press, 1989, pp 45-79.
23. Carreau JP, Mazliak P and Frommel D: Delta 6-, delta 5-fatty acyl-CoA desaturases and gamma-linolenoyl-CoA elongase in regenerating rat liver. Int J Blochem 13: 831-836, 1981.
24. Horrobin DF and Manku MS: Clinical biochemistry of essential fatty acids. In: Omega 6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine (Horrobin DF ed). New York, Alan R Liss, 1990, pp 21-53.
25. Bourre JM, Piciotti M and Dumont O: A6 desaturase in brain and liver during development and aging. Lipids 25: 354-356, 1990.
26. Bourre JM and Piciotti M: Delta-6 desaturation of alpha-linolenic acid in brain and liver during development and aging in the mouse. Neurosci Lett 141: 65-68, 1992.
27. Rivers JPW, Sinclair AJ and Crawford MA: Inability of the cat to desaturate essential fatty acids. Nature 258: 171-173, 1975.
28. Frankel TL and Rivers JPW: The nutritional and metabolic impact of 7-linolenic acid (18-.3(06)) on cats deprived of animal lipid. Br J Nutr 39: 227-231, 1978.
29. Sinclair AJ, Slattery W, McLean JG and Monger EA: Essential fatty acid deficiency and evidence for arachidonate synthesis in the cat. Br J Nutr 46: 93-96, 1981.
30. Davidson BC, Goelst K and Cantrill RC: Limiting the range of polyenoic fatty acids available from purified diets affects the growth of domestic cats. In Vivo 3: 183-186, 1989.
31. Rivers JPW, Hassam AG, Crawford MA and Brambell MR: The inability of the lion, Panthera leo, L. to desaturate linoleic acid. FEBS Letts 67: 269-270, 1976.
32. Davidson BC, Cantrill RC and Varaday D- The reversal of essential fatty acid deficiency symptoms in the cheetah. S Afr J Zool 21: 161-164, 1986.
33. 3H-dopamine release from presynaptic receptors in caudate slices. In Vivo 2: 295-298, 1988.
34. Kim HY, Sawazaki S and Salem N Jr.: Lipoxygenation in rat brain? Blochem Blophys Res Commun 174: 729-734, 1991.
35. Reid MS, Ho LB, Hsu K, Fox L, Tolliver BK, Adams JU, Franco A and Berger SP: Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization. Pharmacol Blochem Behav 71: 37-54, 2002.
36. Williams JH and Bliss TV: An in vitro study of the effect of lipoxygenase and cyclooxygenase inhibitors of arachidonic acid on the induction and maintenance of long-term potentiation in the hippocampus. Neurosci Lett 107: 301-306, 1989.
37. Piomelli D and Greengard P: Lipoxygenase metabolites of arachidonic acid in neuronal transmembrane signalling. TiPS 11: 367-373, 1990.
38. Cass WA, Larson G, Fitzpatrick FA and Zahniser NR: Inhibitors of arachidonic acid metabolism- Effects on rat striatal dopamine release and uptake. J Pharmacol Experimental Therapeut 257: 990-996, 1991.